Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Jan 12, 2024 (filed on Jan 12, 2024)Insider Name:Zhang YanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-104Price:$0.04
-
Dec 21, 2023 (filed on Dec 22, 2023)Insider Name:Kamdar Kim P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10Price:$0.62
-
Apr 26, 2023 (filed on Apr 26, 2023)Insider Name:Zhang YanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Dec 31, 2022 (filed on May 08, 2023)Insider Name:File Justin J.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 5 : Annual Statement of Beneficial Ownership of Securities# or value acquired/disposed of:-30,000Price:--
-
Dec 31, 2022 (filed on Apr 26, 2023)Insider Name:Pelletier Saundra LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:D - Disposition to issuer under Rule 16b-3(e)# or value acquired/disposed of:-50,000Price:--
Filings by filing date
-
Jan 12, 2024 (filed on Jan 12, 2024)Insider Name:Zhang YanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-104Price:$0.04
-
Dec 21, 2023 (filed on Dec 22, 2023)Insider Name:Kamdar Kim P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10Price:$0.62
-
Dec 31, 2022 (filed on May 08, 2023)Insider Name:File Justin J.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 5 : Annual Statement of Beneficial Ownership of Securities# or value acquired/disposed of:-30,000Price:--
-
Apr 26, 2023 (filed on Apr 26, 2023)Insider Name:Zhang YanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Dec 31, 2022 (filed on Apr 26, 2023)Insider Name:Pelletier Saundra LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:D - Disposition to issuer under Rule 16b-3(e)# or value acquired/disposed of:-50,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 12400 High Bluff Drive, Suite 600 SAN DIEGO CA 92130 |
Tel: | 1-858-5501900 |
Website: | https://www.evofem.com |
IR: | See website |
Key People | ||
Saundra L. Pelletier President, Chief Executive Officer | Ivy Zhang Chief Financial Officer, Company Secretary |
Business Overview |
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing advanced products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Phexxi is an advanced gel that works to prevent pregnancy without the use of hormones. Phexxi prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Phexxi is designed to address underserved and unmet needs in the birth control market. Additionally, the Company offers women direct access to Phexxi through its telehealth partner. Using this platform, women can have a telehealth visit with a health care provider (HCP) to determine their eligibility for a Phexxi prescription. |
Financial Overview |
For the fiscal year ended 31 December 2023, Evofem Biosciences Inc revenues increased 8% to $18.2M. Net income applicable to common stockholders totaled $50M vs. loss of $78M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Loss on issuance of financial instrument decrease of 91% to $6.8M (expense). |
Employees: | 37 as of Mar 21, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $48.55M as of Dec 31, 2023 |
Annual revenue (TTM): | $18.22M as of Dec 31, 2023 |
EBITDA (TTM): | -$17.37M as of Dec 31, 2023 |
Net annual income (TTM): | $50.00M as of Dec 31, 2023 |
Free cash flow (TTM): | -$8.97M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $43.27M as of Dec 31, 2023 |
Shares outstanding: | 45,939,509 as of Mar 21, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |